Phase 4 Type 2 Diabetes Trial, Not Yet Recruiting NCT07116928 Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 4 Type 2 Diabetes Trial, Not Yet Recruiting

NCT07116928
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Adults aged 18 or older (male or female).
  • People who have been diagnosed with type 2 diabetes.
  • People who have been diagnosed with chronic kidney disease (CKD) with specific kidney function and protein levels in their urine, measured during the screening period (confirm with trial site for exact values).
  • People whose blood sugar control measure (HbA1c) is between 6.5% and 12%.
  • People who have been taking a stable dose of a specific type of blood pressure/kidney-protective medication (called an ACE inhibitor or ARB) for at least 4 weeks before the start of the trial, unless there is a medical reason not to.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with type 1 diabetes or other less common forms of diabetes.
  • People with a history or medical evidence of kidney disease caused by something other than type 2 diabetes, such as lupus-related kidney disease or certain immune-related kidney conditions.
  • People who have had a kidney transplant.
  • People with a high potassium level in their blood (above 5.5 mmol/L) during the screening period.
  • People with a severe heart failure classification (New York Heart Association Grade IV) during the screening period.
  • People who have experienced a serious health event — such as a dangerous blood sugar crisis, heart attack, unstable chest pain, stroke, mini-stroke, hospitalisation for heart failure, or hospitalisation for urinary tract infection or sudden kidney injury — within the 12 weeks before screening.
  • People currently taking both an ACE inhibitor and an ARB at the same time.
  • People who have taken certain other blood pressure or kidney-related medications (called mineralocorticoid receptor antagonists or direct renin inhibitors) within 8 weeks before the start of the trial.
  • People who have taken immune-suppressing medications or certain biological drugs within 12 weeks before screening.
  • People who have taken a type of diabetes medication called an SGLT-2 inhibitor or GLP-1 receptor agonist within 8 weeks before screening, or who have previously tried an SGLT-2 inhibitor but stopped because it did not work well enough.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +86-0571-89908582

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Registry
ClinicalTrials.gov
Start date
30 November 2025
Est. completion
30 October 2031

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The average change in eGFR as measured by the total slope of eGFR from baseline to week 120

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov